Studies have shown that c-Myc levels are substantially elevated in different EGFR-mutant NSCLC cell lines with acquired resistance to the third-generation EGFR-TKI osimertinib compared with the corresponding parental cell lines; moreover, these increased levels cannot be reduced by osimertinib. This evidence concerns the gene EGFR and non-small cell lung carcinoma.